rs149506518
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PP3_Moderate
The NM_004320.6(ATP2A1):c.521G>A(p.Arg174Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000049 in 1,613,592 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R174W) has been classified as Uncertain significance.
Frequency
Consequence
NM_004320.6 missense
Scores
Clinical Significance
Conservation
Publications
- Brody myopathyInheritance: AR, AD Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet, Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ATP2A1 | NM_004320.6 | c.521G>A | p.Arg174Gln | missense_variant | Exon 6 of 23 | ENST00000395503.9 | NP_004311.1 | |
| ATP2A1 | NM_173201.5 | c.521G>A | p.Arg174Gln | missense_variant | Exon 6 of 22 | NP_775293.1 | ||
| ATP2A1 | NM_001286075.2 | c.146G>A | p.Arg49Gln | missense_variant | Exon 4 of 21 | NP_001273004.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ATP2A1 | ENST00000395503.9 | c.521G>A | p.Arg174Gln | missense_variant | Exon 6 of 23 | 1 | NM_004320.6 | ENSP00000378879.5 | ||
| ATP2A1 | ENST00000357084.7 | c.521G>A | p.Arg174Gln | missense_variant | Exon 6 of 22 | 2 | ENSP00000349595.3 | |||
| ATP2A1 | ENST00000536376.5 | c.146G>A | p.Arg49Gln | missense_variant | Exon 4 of 21 | 2 | ENSP00000443101.1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152156Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000199 AC: 5AN: 250676 AF XY: 0.0000221 show subpopulations
GnomAD4 exome AF: 0.0000513 AC: 75AN: 1461436Hom.: 0 Cov.: 32 AF XY: 0.0000413 AC XY: 30AN XY: 727048 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152156Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74324 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
The c.521G>A (p.R174Q) alteration is located in exon 6 (coding exon 6) of the ATP2A1 gene. This alteration results from a G to A substitution at nucleotide position 521, causing the arginine (R) at amino acid position 174 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Brody myopathy Uncertain:1
This sequence change replaces arginine with glutamine at codon 174 of the ATP2A1 protein (p.Arg174Gln). The arginine residue is moderately conserved and there is a small physicochemical difference between arginine and glutamine. This variant is present in population databases (rs149506518, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with ATP2A1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not provided Uncertain:1
Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at